Business Context and Reporting Period
Company: BioTime, Inc. (Note: Input metadata referenced "Lineage Cell Therapeutics," but the filing text identifies the registrant as BioTime, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: BioTime is a biotechnology company operating in two segments: (1) Plasma volume expanders, primarily the product Hextend, used to treat hypovolemia in surgery and trauma; and (2) Regenerative medicine, operated through subsidiary Embryome Sciences, Inc., focusing on human embryonic stem cell research products and technology.
Key Financial Metrics
| Metric | 2008 | 2007 |
|---|---|---|
| Total Revenue | $1,503,792 | $1,046,121 |
| Net Loss | $(3,780,895) | $(1,438,226) |
| Loss Per Share (Basic/Diluted) | $(0.16) | $(0.06) |
| Cash and Cash Equivalents (Year End) | $12,279 | $9,501 |
| Working Capital Deficit | $(3,269,643) | Not explicitly stated |
| Shareholders' Deficit | $(4,346,814) | $(3,046,389) |
| Accumulated Deficit | $(47,625,392) | $(43,844,497) |
| Debt (Lines of Credit Payable, Net) | $1,885,699 | $716,537 |
Revenue Breakdown (2008): Royalties from product sales ($1,203,453), License fees ($277,999), and Grant income ($22,340).
Expense Breakdown (2008): Research and Development ($1,706,214), General and Administrative ($2,620,210), and Interest Expense ($965,781).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 44% to $1.5 million, driven primarily by a 55% increase in royalties from Hextend sales ($1.2 million vs. $776k in 2007). This was attributed to increased sales to the military and hospitals.
- Expense Increases:
- R&D Expenses: Increased 76% to $1.7 million, primarily due to the launch of the stem cell business (Embryome Sciences), including higher salaries, rent, and lab supplies.
- G&A Expenses: Increased 101% to $2.6 million, driven by stock-based compensation ($379k), stock appreciation rights ($470k), and consulting fees.
- Interest Expense: Increased significantly to $965k (from $232k) due to higher borrowings and a $330k charge for the beneficial conversion of debt into equity.
- Net Loss: Widened to $3.78 million from $1.44 million due to the substantial increase in operating and interest expenses outpacing revenue growth.
- Debt Position: Borrowings under the Revolving Line of Credit increased significantly. As of March 6, 2009, outstanding loans were $3.33 million.
Guidance, Outlook, Risks, and Contingencies
Going Concern Warning: The independent auditors have issued a "going concern" opinion. The company has a working capital deficit of $3.27 million and an accumulated deficit of $47.6 million. Continued operations depend on raising additional capital and generating revenue.
Liquidity and Capital Resources:
- The company relies on a Revolving Line of Credit (collateralized by Hospira royalties) with a $3.5 million limit. Loans mature on April 15, 2009, and bear 12% interest.
- Management states the need to obtain additional debt or equity capital to finance operations. Failure to do so could force curtailment of operations.
Outlook and Strategy:
- Plasma Expanders: Continued reliance on royalties from Hextend (distributed by Hospira in the US and CJ in South Korea). Development of PentaLyte is ongoing but dependent on funding.
- Stem Cells: Focus on near-term commercialization of research products (e.g., ESpan media, ESpy cell lines) rather than therapeutic products, to generate revenue with less capital. Significant revenue from this segment is not expected immediately.
Risks:
- Financing: Uncertainty regarding the availability and terms of future equity or debt financing.
- Regulatory: Dependence on FDA and foreign regulatory approvals for therapeutic products; changes in federal funding for stem cell research.
- Competition: Intense competition in both plasma expanders (generic hetastarch, albumin) and stem cell research.
- Concentration: 80% of 2008 revenue came from a single customer, Hospira.
Investor Verification Checklist
- Debt Maturity: Verify the status of the $3.33 million line of credit maturing April 15, 2009, and whether renewal or refinancing has been secured.
- Cash Runway: Assess current cash balances against monthly burn rate (approx. $3.3M operating expenses in 2008) to determine immediate liquidity risk.
- Revenue Concentration: Monitor Hospira's sales performance, as 80% of revenue is dependent on this single licensee.
- Stem Cell Progress: Evaluate the commercial traction of Embryome Sciences' research products (ESpan, ESpy) to determine if they can offset the lack of therapeutic revenue.
- Dilution Risk: Review recent and potential future equity issuances used to service debt or raise capital, noting the significant share count increase in 2008.